Modulatory Role of Ginsenosides Injected Intrathecally or Intracerebroventricularly in the Production of Antinociception Induced by Kappa-Opioid Receptor Agonist Administered Intracerebroventricularly in the Mouse

Abstract

We examined the effects of ginseng total saponin and several ginsenosides injected intrathecally (i.t.) or intracerebroventricularly (i.c.v.) on the antinociception induced by U50, 488H (trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeocetamide; a kappa opioid receptor agonist) administered i.c.v. The tail-flick test was used as an analgesic assay. Total saponin fraction at doses of 0.1 to 20 μg, which when administered intrathecally (i.t.) or intracerebroventricularly (i.c.v.) alone did not affect the latencies of tail-flick threshold, attenuated dose-dependently the inhibition of the tail-flick response induced by U50, 488H (60 μg) administered i.c.v. The duration of antagonistic action of total saponin fraction against U50, 488H-induced antinociception lasted at least for 6 h. Various doses (from 0.1 to 1 μg) of ginsenosides R_b1, R_b2, R_c, R_d, and Rg₁, but not R_e, injected i.t. dose-dependently attenuated antinociception induced by U50, 488H administered i.c.v. Furthermore, various doses (from 1 to 10 μg) of ginsenosides R_b2 and R_e, but not R_b1, R_c, R_d, and R_g1, injected i.c.v. dose-dependently attenuated antinociception induced by U50, 488H administered i.c.v. In summary, ginsenosides R_b1, R_b2, R_c, R_d, and R_g1 administered spinally appear to be responsible for blocking the antinociception induced by U50, 488H administered supraspinally, whereas ginsenosides R_b2 and R_e administered supraspinally appear to be responsible for blocking the antinociception induced by U50, 488H administered supraspinally.

Abbreviations

i.c.v.:intracerebroventricular i.t.:intrathecally U50, 488HA:trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeocetamide

Key words

Total saponin fraction - ginsenosides - U50 - 488H - antinociception

References

• 1 Millan  M J,, Morris  B J,, Herz  A.. J. Pharmacol. Exp. Ther.. 1988;;  247 721-8
• 2 Suh  H H,, Tseng  L F,, Li  C H.. Neuropharmacology. 1988;;  27 957-63
• 3 Roerig  S C,, Fujimoto  J M.. J. Pharmacol. Exp. Ther.. 1989;;  249 762-68
• 4 Tseng  L F,, Collins  K A.. J. Pharmacol. Exp. Ther.. 1993;;  266 1430-38
• 5 Han  J S,, Xie  C W.. Life Sci.. 1982;;  31 1781-84
• 6 Nakazawa  T,, Ikeda  M,, Kaneko  T,, Yamatsu  K.. Peptides. 1985;;  75-8
• 7 Spampinato  S,, Candeletti  S.. Eur. J. Pharmacol.. 1985;;  110 21-30
• 8 Porreca  F,, Mosberg  H I,, Omnaas  J R,, Burks  T F,, Cowan  A.. J. Pharmacol. Exp. Ther.. 1987;;  240 890-94
• 9 Welch  S P,, Singha  A K,, Dewey  W L.. J. Pharmacol. Exp. Ther.. 1989;;  251 1-8
• 10 Tseng  L F,, Collins  K A,, Kampine  J P.. Eur. J. Pharmacol.. 1994;;  258 R1-3
• 11 Suh  H W,, Song  D K,, Choi  Y S,, Kim  Y H.. Neuropeptides. 1996;;  30 485-90
• 12 Ramarao  P,, Bhargava  H N.. Gen. Pharmacol.. 1990;;  21 877-80
• 13 Kim  H S,, Oh  K W,, Rheu  H M,, Kim  S H.. Pharmacol. Biochem. Behav.. 1992;;  42 587-93
• 14 Kim  H S,, Ann  S H,, Seong  Y H,, Kim  S H,, Oh  K W.. Korean J. Ginseng Sci.. 1992;;  16 93-8
• 15 Kim  H S,, Chung  M W,, Jang  WK,, Park  C G,, Oh  K W.. Korean J. Ginseng Sci.. 1993;;  17 22-8
• 16 Suh  H W,, Song  D K,, Kim  Y H.. Gen. Pharmacol.. 1997;;  29 873-7
• 17 Suh  H W,, Song  D K,, Huh  S O,, Kim  Y H.. Korean J. Ginseng Sci.. 1997;;  21 109-14
• 18 D'Amour  F E,, Smith  D L.. J. Pharmacol. Exp. Ther.. 1941;;  72 74-9
• 19 Haley  T J,, McKormick  W G.. Br. J. Pharmacol.. 1957;;  12 12-5
• 20 Hylden  J LK,, Wilcox  G L.. Eur. J. Pharmacol.. 1980;;  67 313-16
• 21 Xu  J Y,, Tseng  L F.. J. Pharmacol. Exp. Ther.. 1995;;  274 8-16
• 22 Chen  X,, Lee  T J.. Br. J. Pharmacol.. 1995;;  115 15-8
• 23 Kim  N D,, Kang  S Y,, Schini  V B.. Gen. Pharmacol.. 1995;;  25 1071-7